研报中提出对于诺华增长率的担忧观点，预计在仿制药市场竞争加剧之际，经过三到四年高个位数至低 双位数级别的销售额显著增长时期之后，其整体增长将"在结构层面上有所下调"。尽管存在这些增长层 面的担忧因素，高盛统计数据显示，该公司仍保持出色的财务基本面健康评分，过去十二个月营收增长 达12.95%。(格隆汇) | NVS 诺华制药 | | | | --- | --- | --- | | 127.700 ↑ +1.150 +0.91% | | 收盘价 09/11 15:59 美东 | | 124.180 ↓ -3.520 -2.76% | | 盘前价 09/12 04:24 美东 | | 三 72 24 S ~ 9 日 ♥ 白选 | | ● 快捷交易 | | 最高价 128.050 | 开盘价 127.520 | 成交量 92.07万 | | 最低价 127.345 | 昨收价 126.550 | 成交额 1.18亿 | | 平均价 127.646 | 市盈率 M 18.61 | 总市值 2472.08亿 (1) | | 振 幅 0.56% | 市盈率(静) 21.75 | 总股本 19.36亿 | | 换手率 0. ...

目标价与评级调整 - 美银将诺瓦瓦克斯医药目标价从9美元下调至7美元 [2] - 美银将诺瓦瓦克斯医药评级从"中性"下调至"跑输大市" [2] 机构观点与目标价 - 花旗首次覆盖诺瓦瓦克斯医药并给予"卖出"评级 [2] - 花旗设定诺瓦瓦克斯医药目标价为6美元 [2]

公司股价表现 - 港股石药集团股价下跌超过5%，创下三周以来最大单日跌幅 [1] 评级调整 - Jefferies将石药集团股票评级下调至"落后大盘" [1] 评级原因 - 分析师认为公司所有利好因素均已反映在当前股价中 [1] - 公司关键产品销售持续面临阻力 [1]

Iovance Biotherapeutics (IOVA -5.68%) didn't quite end the stock trading week on a high note. The company's shares were dinged by almost 6% that day, due largely to an analyst's recommendation downgrade. This occurred on a generally positive day for equities, as the S&P 500 index managed to land in the black with a 0.7% rise.A bearish adjustmentWell before market open, UBS pundit David Dai flipped the switch on his Iovance recommendation, changing it to neutral from his previous buy. Compounding that signif ...